Andere talen Kyowa Kirin Co., Ltd.

Aandelen

4151

JP3256000005

Farmaceutische producten

Beurs gesloten - Japan Exchange Andere beurzen 08:30:00 13-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2.489,50 ^JPY	0,00%		+2,28%	+4,80%

12/06	Kura Oncology, Inc. en Kyowa Kirin Co., Ltd. rapporteren positieve bijgewerkte combinatiegegevens voor ziftomenib bij nieuw gediagnosticeerde AML tijdens het congres van de European Hematology Association in 2025.	CI
12/06	Kura Oncology meldt dat onderzoek naar ziftomenib volledige remissie bereikt bij acute myeloïde leukemie	MT

Andere talen

Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress	12/06
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia	12/06
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress	12/06
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Report Positive Pivotal Ziftomenib Monotherapy Data At 2025 ASCO Annual Meeting	03/06
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data	03/06
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory Npm1-Mutant Aml	02/06
Kura Oncology, Kyowa Get FDA Acceptance, Priority Review of New Drug Application for Ziftomenib	02/06
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML	02/06
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting	22/05
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress	14/05
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation At the 2025 European Hematology Association Congress	14/05
Kyowa Kirin : Transcript of Results Briefing Fiscal 2025 First Quarter	08/05
Kyowa Kirin : Introduction of Special Voluntary Early Retirement Program	07/05
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh	07/05
Kyowa Kirin Profit Plunges 58% in Q1; Shares Down 3%	02/05
Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025 First Quarter	01/05
Kyowa Kirin : Results Presentation Fiscal 2025 First Quarter	01/05
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2025 First Quarter	01/05
Kyowa Kirin : Completed Construction of a New Biopharmaceutical DS Manufacturing Facility at Takasaki Plant Acceleration of development through the establishment of an innovative global manufacturing structure	11/04
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA	08/04
Kyowa Kirin : Shareholder Voting Result at the 102nd Ordinary General Meeting of Shareholders	21/03
Kyowa Kirin : Notice of Resolutions of the 102nd Ordinary General Meeting of Shareholders	21/03
Kyowa Kirin to Dispose of Treasury Shares for Executive Compensation	21/03
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS	10/03
Amgen and Kyowa Kirin Co., Ltd. Provide Top-Line Results from Roccatinlimab Phase 3 Initiative Study in Results with Moderate to Severe Atopic Dermatitis	08/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kyowa Kirin Co., Ltd.

Aandelen

4151

JP3256000005

Farmaceutische producten

Andere talen

Filters